financetom
Business
financetom
/
Business
/
CVS Health cuts 2024 profit forecast on elevated medical costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CVS Health cuts 2024 profit forecast on elevated medical costs
Aug 7, 2024 4:10 AM

Aug 7 (Reuters) - CVS Health Corp ( CVS ) on Wednesday

cut its 2024 profit forecast, hit by increased medical costs at

its health insurance unit as demand for healthcare services

remained elevated.

The healthcare conglomerate also announced a multi-year plan

to save $2 billion in costs after recording a sharp decline in

its second-quarter profit.

The company's Aetna insurance unit, along with peers, has

been struggling with high costs from increased use of medical

services by members of Medicare Advantage plans for adults aged

65 and older or for those with disabilities.

CVS said Brian Kane, chief of the health care benefits unit

that runs Aetna, is leaving the company effective immediately.

Karen Lynch, who was president of Aetna before becoming CVS's

CEO, will assume direct leadership of the unit, the company

said.

Lynch and CFO Tom Cowhey will oversee day-to-day management

of this business, while Aetna veteran and Chief Strategy Officer

Katerina Guerraz has been made chief operating officer of the

unit.

CVS' adjusted profit dropped to $1.83 per share in the

quarter ended June 30, from $2.21 last year, but was still ahead

of LSEG estimates by 10 cents. The estimates have come down

sharply in the past month.

The company's healthcare benefit ratio - the percentage of

premiums spent on medical care - also rose more than 3

percentage points to 89.6%, but was still lower than estimates

of 90.5%.

Aetna also offers Medicaid plans for lower income people,

where costs have also been high due to sicker patients gaining

coverage.

CVS cut its annual profit forecast to a range of $6.40 to

$6.65 from at least $7.00 earlier, marking at least its fourth

cut of the outlook.

The company recorded total quarterly revenue of $91.2

billion, missing analysts' estimates of $91.5 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Eli Lilly beats Q1 profit estimates on strength of diabetes drug
Eli Lilly beats Q1 profit estimates on strength of diabetes drug
May 25, 2025
May 1 (Reuters) - Eli Lilly ( LLY ) on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro. On an adjusted basis, the U.S. drugmaker earned $3.34 per share for the quarter, compared with analysts' estimates of $3.02 per share, according to LSEG data. (Reporting...
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
May 25, 2025
May 1 (Reuters) - Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs. The drugmaker has been counting on newer launches such as genetic disorder drug Skyclarys as demand falls for its once top-selling multiple sclerosis medicines in the face of stiff competition...
CVS Health's Q1 Adjusted Earnings, Revenue Rise; Raises 2025 Adjusted EPS Guidance
CVS Health's Q1 Adjusted Earnings, Revenue Rise; Raises 2025 Adjusted EPS Guidance
May 25, 2025
06:49 AM EDT, 05/01/2025 (MT Newswires) -- CVS Health ( CVS ) reported Q1 adjusted earnings Thursday of $2.25 per diluted share, up from $1.31 a year earlier. Analysts polled by FactSet expected $1.70. Revenue for the quarter ended March 31 was $94.59 billion, compared with $88.44 billion a year earlier. Analysts surveyed by FactSet expected $93.66 billion. For 2025,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved